Panacise Bio

Overview

Faculty Founders

Rihe Liu, PhD

School of Pharmacy

Core Technology and Enabling Features

Universal targeting system for immunotherapy; General Antigen Receptor (GAR) as next generation cancer immunothearpy.

Publications

Incorporation

NEO: Delaware LLC

Main Contact

Andrew Kant, NEO, akant@ad.unc.edu

Problem/Need

Panacise Bio LLC is developing a next generation cancer immunotherapy platform (GAR-T) aimed at providing a self-assembling, universal and versatile approach to treating cancer.

Status

IP Status

PCT (PCT/US2014/058257) Methods and compositions for self-assembly system of nanoparticles and microparticles for multi-targeting specificity

License

Pre-license

Funding

NEO, STTR application submitted

Technology and Product Development

Application identified as immunotherapeutic agents which combines advantages of CAR-T cell therapy and immune checkpoint inhibition. Pilot study scheduled for Feb 2016.

Space

Founders’ lab

Management

NEO/KickStart

Panacise Bio - Google Slides